KPV

Preclinical Research

Also known as: Lys-Pro-Val, α-MSH tripeptide

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its potent anti-inflammatory properties, particularly in gut epithelial models and inflammatory bowel disease research.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

Immune Support
Skin & Wound Healing
Gut & GI Health

Mechanism of Action

Research suggests KPV acts through melanocortin receptors (MC1R, MC3R) and can penetrate gut epithelial cells to directly inhibit NF-κB signaling, reducing pro-inflammatory cytokine production. Animal studies show efficacy in colitis models.

Safety Notes

Primarily studied in animal and cell culture models. Very limited human clinical data. Generally considered low-toxicity given its natural origin.

Want to learn more?

Ask Research Chat about KPV

Research Profile

Half-Life

Short (peptide, subject to rapid degradation)

Administration

oral, topical, subcutaneous injection

Legal Status (US)

Research chemical. Not FDA-approved for human therapeutic use.

20 indexed research passages

Related Peptides

Tropisetron

Tropisetron is a 5-HT3 receptor antagonist and alpha7 nicotinic acetylcholine receptor agonist approved in various countries for chemotherapy-induced nausea. Research has also examined its potential roles in pain management, fibromyalgia, and cognitive enhancement through its dual receptor pharmacology.

Larazotide

Larazotide is a synthetic octapeptide that acts as a tight junction regulator in gut epithelium. Research has examined its potential to reduce intestinal permeability ('leaky gut') in celiac disease and other inflammatory gut conditions by antagonizing the zonulin pathway.

LL-37

LL-37 is the only known human cathelicidin antimicrobial peptide, derived from the C-terminal cleavage of hCAP18 and produced primarily by epithelial cells, neutrophils, and macrophages. Research has examined its roles in innate immune defense, wound healing, angiogenesis promotion, and modulation of inflammatory responses, as well as its potential as a therapeutic agent.

Roxadustat

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in multiple countries including China, Japan, and the EU for the management of anemia associated with chronic kidney disease. It stimulates endogenous erythropoietin production by stabilizing HIF-alpha proteins.